Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2025 · 10-Q
Revenue$149.82M$149.82M+4.3% vs Q1 2024 Net Income-$11.83M-$11.83MN/M vs Q1 2024 EPS Diluted-$0.21-$0.21— vs Q1 2024 Operating Income-$10,256,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived$30,272,000−20.7% Margins · derivedOperating margin-6.8%−4.7 pt vs Q1 2024
Net margin-7.9%−8.0 pt vs Q1 2024
ended Mar 31, 2025 · filed May 6, 2025 · 36 d after period end